LiquipatchTM. In 2001, we entered into a global licensing agreement with Novartis Consumer Health SA for the use of our Liquipatch drug-delivery system in topical antifungal applications. Novartis anticipates initial European launch of a product using the Liquipatch technology in 2006

Exhibit 10.16

Summary Compensation Information for Named Executive Officers and Directors

     Base Salary/Bonus Compensation. The table below sets forth the 2006 annual base salary levels of the Named Executive Officers in the Company’s proxy statement for its Annual Meeting of Stockholders held on April 22, 2005, and who are expected to be listed as the Named Executive Officers in the Company’s Proxy Statement for the Annual Meeting of Stockholders to be held in 2006.

     Effective January 1, 2005, the annual incentive range for bonus awards for Named Executive Officers for 2005 was set at between zero and sixty percent of base salary for each Named Executive Officer except Mr. Wiggans. The range and target bonus for Mr. Wiggans for 2005 was set at the discretion of the Board of Directors. The metrics used for measurement of bonus awards for 2005 included the Company’s success in achieving specific Company-wide goals as well as the Named Executive Officers’ success in achieving individual and department goals in 2005. The table below sets forth information regarding bonus compensation for our Named Executive Officers paid in 2006 for service provided in 2005.

	Name and Position			Year					2006 Base Salary					Bonus for 2005 Performance
	Thomas G. Wiggans Chief Executive Officer				2006				$	575,000				$	325,000
	C. Gregory Vontz President and Chief Operating Officer				2006					422,000					190,000
	Lincoln Krochmal Executive Vice President, Research and Product Development				2006					400,000					154,000
	John L. Higgins Executive Vice President, Finance and Corporate Development and Chief Financial Officer				2006					360,000					167,000
	Katrina J. Church Executive Vice President, Legal Affairs, General Counsel and Secretary				2006					305,000					97,000

     Acceleration of Option Vesting. The Company accelerated the vesting of certain unvested incentive and non-qualified stock options previously awarded to employees and Outside Directors with option exercise prices greater than $18.00, effective November 7, 2005, as described in the Company’s Current Report on Form 8-K dated November 23, 2005 and filed with the SEC on November 30, 2005.

     The Named Executive Officers and Outside Directors whose stock options were accelerated pursuant to this decision were:

	Named Executive Officer			No. of Unvested Options Accelerated					Exercise Price
	Thomas G. Wiggans				200,000				$	18.05
					135,000					23.35
	C. Gregory Vontz				112,000					18.05
					90,000					23.35
	Lincoln Krochmal				25,000					18.05
					45,000					23.35
	John L. Higgins				90,000					18.05
					81,000					23.35
	Katrina J. Church				72,000					18.05
					45,000					23.35
	Outside Directors
	R. Andrew Eckert				15,000					28.00
	Carl B. Feldbaum				30,000					22.08
	Denise Gilbert				15,000					18.01
					15,000					28.00
	John C. Kane				15,000					28.00
	Thomas Kiley				15,000					28.00
	Leon Panetta				15,000					28.00
	G. Kirk Raab				15,000					28.00

     Restricted Stock Purchase Awards. On February 1, 2006, the Compensation Committee also approved grants of restricted stock purchase awards to each of the Named Executive Officers, as described in the Company’s Current Report on Form 8-K dated February 1, 2006 and filed with the SEC on February 7, 2006.

     No stock options were granted to the Named Executive Officers in 2006 as part of their compensation for 2005.

     Information regarding the compensation paid and awarded to the Named Executive Officers and Outside Directors for the year ended December 31, 2005 will be provided in the definitive proxy statement for the Company’s 2006 Annual Meeting of Stockholders.